Browse the corpus

REFERENCES Arlin ZA, “A Special Role for Amsacrine in the Treatment of Acute Leukemia,” Cancer Invest , 1989, 7(6):607-9. [PubMed 2630010 ] Arlin ZA, Feldman, E. Kempin S, et al, “Amsacrine With High-Dose Cytarabine is Highly Effective Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia in Adults,” Blood , 1988, 72(2):433-5. [PubMed 3165293 ] Hall SW, Friedman J, Legha SS, et al, “Human Pharmacokinetics of a New Acridine Derivative, 4'-(9-Acridinylamino)methanesulfon-m-anisidide (NSC 249992),” Cancer Res , 1983, 43(7):3422-6. [PubMed 6687834 ] Hornedo J and Van Echo DA, “Amsacrine (m-AMSA): A New Antineoplastic Agent. Pharmacology, Clinical Activity and Toxicity,” Pharmacotherapy , 1985, 5(2):78-90. [PubMed 2582401 ] Koren G, Beatty K, Seto A, et al, “The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents,” Ann Pharmacother , 1992, 26(3):363-71. [PubMed 1554959 ] Louie AC and Issell BF, “Amsacrine (AMSA) - A Clinical Review,” J Clin Oncol , 1985, 3(4):562-92. [PubMed 3884748 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Pai VB and Nahata MC, “Cardiotoxicity of Chemotherapuetic: Incidence, Treatment and Prevention,” Drug Saf , 2000, 22(4):263-302. [PubMed 10789823 ] Topic 9343 Version 37.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]